Oseltamivir Zentiva (Oseltamivir Phosphate)

Oseltamivir Zentiva, a neuraminidase inhibitor, is used to manage seasonal influenza infections and to prevent disease in individuals who have been exposed to the virus.

• Influenza A infection: shortens the duration of fever, cough and other symptoms when treatment is started within 48 hours of onset.
• Influenza B infection: similarly reduces illness length and severity, aiding faster recovery in confirmed cases.
• Influenza prophylaxis: prevents onset of illness in individuals who have been exposed to the virus, when taken as prescribed for the recommended period.

• Oseltamivir phosphate is a prodrug that is converted in the liver to the active metabolite oseltamivir carboxylate. The active metabolite binds to the active site of the influenza virus neuraminidase enzyme, blocking its activity. By inhibiting neuraminidase, the release of newly formed viral particles from infected cells is prevented, limiting viral spread within the respiratory tract.

Oseltamivir Zentiva may cause a range of adverse reactions, which are generally categorized as common or serious and vary in frequency and intensity. Patients should be advised to report any new or worsening symptoms promptly.

Common Side Effects

• Nausea: mild to moderate stomach upset
• Vomiting: occasional emesis
• Headache: transient cranial pain
• Diarrhea: loose stools
• Abdominal pain: crampy discomfort
• Cough: dry throat irritation

Serious or Rare Side Effects

• Allergic reactions: rash, urticaria, or Stevens‑Johnson syndrome
• Neuropsychiatric events: confusion, delirium, or abnormal behavior
• Severe skin reactions: toxic epidermal necrolysis or extensive blistering
• Hepatic injury: elevated liver enzymes or hepatitis
• Hemolytic anemia: destruction of red blood cells in predisposed patients

When prescribing Oseltamivir Zentiva, several precautionary measures should be considered to ensure safe use.

• Renal impairment: dose adjustment may be required in patients with reduced kidney function.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Pediatric use: safety and appropriate dosing should be confirmed for children.
• Concomitant medications: review for potential interactions, especially with neuraminidase inhibitors.
• Underlying cardiac disease: monitor for any cardiac complications.
• Store below 25°C: keep in the original pack, protect from moisture.

Oseltamivir Zentiva can interact with other medicines, potentially affecting its efficacy or safety profile.

Major Interactions (Avoid)

• Ritonavir: greatly increases oseltamivir levels.
• Probenecid: reduces renal clearance, raising plasma concentration.
• Other neuraminidase inhibitors (e.g., zanamivir): no added benefit, higher toxicity risk.
• Azithromycin: may increase QT prolongation risk.

Moderate Interactions (Monitor Closely)

• Aspirin/NSAIDs: watch for increased bleeding.
• Warfarin: monitor INR for anticoagulant changes.
• Live attenuated influenza vaccine: possible reduced efficacy.
• St. John’s wort: may lower antiviral effect.
• Carbocisteine: could affect drug absorption.